Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. (VRDN) Stock Overview

Explore Viridian Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

VRDN●NASDAQ
HealthcareBiotechnology
$19.27
$0.010(0.05%)
U.S. Market opens in 2h 23m

Viridian Therapeutics, Inc. (VRDN)

Meyka AI Score

Z

Key Financials

Market Cap1.7B
P/E Ratio-5.51
EPS (TTM)$-3.32
ROE-0.61%
Fundamental Analysis

AI Price Forecasts

1 Month$21.04
3 Months$31.07
1 Year Target$26.43

VRDN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Viridian Therapeutics, Inc. (NASDAQ: VRDN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Viridian Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VRDN on the NASDAQ shows an RSI of 57.73, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $26.43 for the NASDAQ listing.

Key metrics behind Viridian Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.51 and a market capitalization of 1.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VRDN on the NASDAQ.

Price Performance (NASDAQ: VRDN)

1-Day Change
0.05%
5-Day Change
8.75%
1-Month Change
11.26%
3-Month Change
40.35%
6-Month Change
-41.48%
Year-to-Date (YTD) Change
-38.08%
1-Year Change
10.18%
3-Year Change
-4.22%
5-Year Change
12.76%
All-Time (Max) Change
-99.06%

Contact Information

https://www.viridiantherapeutics.com
617 272 4600
221 Crescent Street, Waltham, MA, 02453

Company Facts

2,520 Employees
IPO DateJun 18, 2014
CountryUS
Actively Trading

Frequently Asked Questions